0	9	Induction	Induction	NNP
10	12	of	of	IN
13	24	endothelial	endothelial	JJ
25	29	cell	cell	NN
30	37	surface	surface	NN
38	46	adhesion	adhesion	NN
47	56	molecules	molecule	NNS
57	59	by	by	IN
60	65	tumor	tumor	NN
66	74	necrosis	necrosis	NN
75	81	factor	factor	NN
82	84	is	be	VBZ
85	92	blocked	block	VBN
93	95	by	by	IN
96	103	protein	protein	NN
104	112	tyrosine	tyrosine	NN
113	124	phosphatase	phosphatase	NN
125	135	inhibitors	inhibitor	NNS
135	136	:	:	:
137	141	role	role	NN
142	144	of	of	IN
145	148	the	the	DT
149	156	nuclear	nuclear	JJ
157	170	transcription	transcription	NN
171	177	factor	factor	NN
178	186	NF-kappa	NF-kappa	NNP
187	189	B.	B.	NNP
191	197	Recent	recent	JJ
198	205	studies	study	NNS
206	210	from	from	IN
211	214	our	our	PRP$
215	225	laboratory	laboratory	NN
226	230	have	have	VBP
231	240	indicated	indicate	VBN
241	245	that	that	IN
246	253	protein	protein	NN
254	262	tyrosine	tyrosine	NN
263	274	phosphatase	phosphatase	NN
275	276	(	(	(
276	282	PTPase	ptpase	NN
282	283	)	)	)
284	294	inhibitors	inhibitor	NNS
295	298	can	can	MD
299	312	down-modulate	down-modulate	VB
313	316	the	the	DT
317	322	tumor	tumor	NN
323	331	necrosis	necrosis	NN
332	338	factor	factor	NN
339	340	(	(	(
340	353	TNF)-mediated	tnf)-mediated	JJ
354	364	activation	activation	NN
365	367	of	of	IN
368	371	the	the	DT
372	379	nuclear	nuclear	JJ
380	393	transcription	transcription	NN
394	400	factor	factor	NN
401	409	NF-kappa	NF-kappa	NNP
410	411	B	B	NNP
412	414	in	in	IN
415	420	ML-1a	ML-1a	NNP
420	421	,	,	,
422	423	a	a	DT
424	433	monocytic	monocytic	JJ
434	438	cell	cell	NN
439	443	line	line	NN
444	445	(	(	(
445	450	Singh	Singh	NNP
451	454	and	and	CC
455	463	Aggarwal	Aggarwal	NNP
463	464	,	,	,
465	467	J.	J.	NNP
468	473	Biol.	Biol.	NNP
474	479	Chem.	Chem.	NNP
480	484	1995	1995	CD
484	485	:	:	:
486	489	270	270	CD
489	490	:	:	:
491	496	10631	10631	CD
496	497	)	)	)
497	498	.	.	.

499	504	Since	since	IN
505	508	TNF	TNF	NNP
509	511	is	be	VBZ
512	515	one	one	CD
516	518	of	of	IN
519	522	the	the	DT
523	528	major	major	JJ
529	537	inducers	inducer	NNS
538	540	of	of	IN
541	548	various	various	JJ
549	557	adhesion	adhesion	NN
558	567	molecules	molecule	NNS
568	570	in	in	IN
571	576	human	human	JJ
577	588	endothelial	endothelial	JJ
589	594	cells	cell	NNS
595	598	and	and	CC
599	604	their	their	PRP$
605	615	expression	expression	NN
616	618	is	be	VBZ
619	624	known	know	VBN
625	627	to	to	TO
628	635	require	require	VB
636	639	the	the	DT
640	650	activation	activation	NN
651	653	of	of	IN
654	662	NF-kappa	NF-kappa	NNP
663	664	B	B	NNP
664	665	,	,	,
666	668	we	we	PRP
669	677	examined	examine	VBD
678	681	the	the	DT
682	688	effect	effect	NN
689	691	of	of	IN
692	698	PTPase	PTPase	NNP
699	709	inhibitors	inhibitor	NNS
710	712	on	on	IN
713	716	the	the	DT
717	729	TNF-mediated	tnf-mediated	JJ
730	739	induction	induction	NN
740	742	of	of	IN
743	756	intracellular	intracellular	JJ
757	765	adhesion	adhesion	NN
766	774	molecule	molecule	NN
775	776	(	(	(
776	783	ICAM)-1	ICAM)-1	NNP
783	784	,	,	,
785	793	vascular	vascular	JJ
794	798	cell	cell	NN
799	807	adhesion	adhesion	NN
808	816	molecule	molecule	NN
817	818	(	(	(
818	825	VCAM)-1	vcam)-1	NN
826	829	and	and	CC
830	841	endothelial	endothelial	JJ
842	851	leukocyte	leukocyte	NN
852	860	adhesion	adhesion	NN
861	869	molecule	molecule	NN
870	871	(	(	(
871	878	ELAM)-1	elam)-1	NN
878	879	.	.	.

880	884	Like	like	IN
885	890	ML-1a	ML-1a	NNP
890	891	,	,	,
892	897	human	human	JJ
898	904	dermal	dermal	JJ
905	916	microvessel	microvessel	NN
917	928	endothelial	endothelial	JJ
929	934	cells	cell	NNS
935	936	(	(	(
936	940	MVEC	MVEC	NNP
940	941	)	)	)
942	949	treated	treat	VBN
950	954	with	with	IN
955	958	TNF	TNF	NNP
959	966	rapidly	rapidly	RB
967	976	activated	activate	VBD
977	978	(	(	(
978	984	within	within	IN
985	987	30	30	CD
988	991	min	min	NN
991	992	)	)	)
993	1001	NF-kappa	NF-kappa	NNP
1002	1003	B	B	NNP
1003	1004	;	;	:
1005	1009	this	this	DT
1010	1016	effect	effect	NN
1017	1020	was	be	VBD
1021	1031	completely	completely	RB
1032	1041	abolished	abolish	VBN
1042	1044	by	by	IN
1045	1057	co-treatment	co-treatment	NN
1058	1062	with	with	IN
1063	1075	phenylarsine	phenylarsine	NN
1076	1081	oxide	oxide	NN
1082	1083	(	(	(
1083	1086	PAO	PAO	NNP
1086	1087	)	)	)
1087	1088	,	,	,
1089	1090	a	a	DT
1091	1099	specific	specific	JJ
1100	1109	inhibitor	inhibitor	NN
1110	1112	of	of	IN
1113	1119	PTPase	PTPase	NNP
1119	1120	.	.	.

1121	1124	The	the	DT
1125	1134	induction	induction	NN
1135	1137	of	of	IN
1138	1144	ICAM-1	ICAM-1	NNP
1144	1145	,	,	,
1146	1152	VCAM-1	VCAM-1	NNP
1152	1153	,	,	,
1154	1157	and	and	CC
1158	1164	ELAM-1	elam-1	NN
1165	1167	by	by	IN
1168	1171	TNF	TNF	NNP
1172	1174	in	in	IN
1175	1179	MVEC	MVEC	NNP
1180	1188	occurred	occur	VBD
1189	1195	within	within	IN
1196	1197	6	6	CD
1198	1199	h	h	NN
1200	1203	and	and	CC
1204	1207	was	be	VBD
1208	1212	also	also	RB
1213	1223	completely	completely	RB
1224	1238	down-regulated	down-regulate	VBN
1239	1241	by	by	IN
1242	1245	PAO	PAO	NNP
1246	1248	in	in	IN
1249	1250	a	a	DT
1251	1265	dose-dependent	dose-dependent	JJ
1266	1272	manner	manner	NN
1272	1273	.	.	.

1274	1277	PAO	pao	NN
1278	1281	was	be	VBD
1282	1287	found	find	VBN
1288	1290	to	to	TO
1291	1293	be	be	VB
1294	1303	effective	effective	JJ
1304	1308	even	even	RB
1309	1313	when	when	WRB
1314	1319	added	add	VBN
1320	1321	3	3	CD
1322	1323	h	h	NN
1324	1329	after	after	IN
1330	1333	TNF	TNF	NNP
1333	1334	,	,	,
1335	1345	suggesting	suggest	VBG
1346	1347	a	a	DT
1348	1353	rapid	rapid	JJ
1354	1358	mode	mode	NN
1359	1361	of	of	IN
1362	1368	action	action	NN
1369	1371	of	of	IN
1372	1376	this	this	DT
1377	1386	inhibitor	inhibitor	NN
1386	1387	.	.	.

1388	1395	Besides	besides	IN
1396	1399	PAO	PAO	NNP
1399	1400	,	,	,
1401	1406	other	other	JJ
1407	1417	inhibitors	inhibitor	NNS
1418	1420	of	of	IN
1421	1427	PTPase	PTPase	NNP
1427	1428	,	,	,
1429	1438	including	include	VBG
1439	1450	pervanadate	pervanadate	NN
1451	1454	and	and	CC
1455	1462	diamide	diamide	NN
1462	1463	,	,	,
1464	1468	also	also	RB
1469	1476	blocked	block	VBD
1477	1490	TNF-dependent	tnf-dependent	JJ
1491	1499	NF-kappa	NF-kappa	NNP
1500	1501	B	B	NNP
1502	1512	activation	activation	NN
1513	1516	and	and	CC
1517	1526	induction	induction	NN
1527	1529	of	of	IN
1530	1533	all	all	PDT
1534	1537	the	the	DT
1538	1543	three	three	CD
1544	1552	adhesion	adhesion	NN
1553	1561	proteins	protein	NNS
1561	1562	.	.	.

1563	1573	Consistent	consistent	JJ
1574	1578	with	with	IN
1579	1584	these	these	DT
1585	1592	results	result	NNS
1592	1593	,	,	,
1594	1597	the	the	DT
1598	1608	attachment	attachment	NN
1609	1611	of	of	IN
1612	1621	monocytes	monocyte	NNS
1622	1624	to	to	TO
1625	1629	MVEC	MVEC	NNP
1630	1633	was	be	VBD
1634	1638	also	also	RB
1639	1646	blocked	block	VBN
1647	1649	by	by	IN
1650	1653	the	the	DT
1654	1660	PTPase	PTPase	NNP
1661	1671	inhibitors	inhibitor	NNS
1671	1672	.	.	.

1673	1677	Thus	thus	RB
1677	1678	,	,	,
1679	1686	overall	overall	RB
1686	1687	,	,	,
1688	1691	our	our	PRP$
1692	1699	results	result	NNS
1700	1711	demonstrate	demonstrate	VBP
1712	1716	that	that	IN
1717	1718	a	a	DT
1719	1725	PTPase	ptpase	NN
1726	1728	is	be	VBZ
1729	1737	involved	involve	VBN
1738	1744	either	either	CC
1745	1753	directly	directly	RB
1754	1756	or	or	CC
1757	1767	indirectly	indirectly	RB
1768	1770	in	in	IN
1771	1774	the	the	DT
1775	1782	pathway	pathway	NN
1783	1790	leading	lead	VBG
1791	1793	to	to	TO
1794	1797	the	the	DT
1798	1807	induction	induction	NN
1808	1810	of	of	IN
1811	1822	endothelial	endothelial	JJ
1823	1827	cell	cell	NN
1828	1836	adhesion	adhesion	NN
1837	1846	molecules	molecule	NNS
1847	1849	by	by	IN
1850	1853	TNF	TNF	NNP
1853	1854	.	.	.

1855	1862	Because	because	IN
1863	1865	of	of	IN
1866	1871	their	their	PRP$
1872	1876	role	role	NN
1877	1879	in	in	IN
1880	1884	cell	cell	NN
1885	1893	adhesion	adhesion	NN
1893	1894	,	,	,
1895	1901	PTPase	PTPase	NNP
1902	1905	may	may	MD
1906	1913	provide	provide	VB
1914	1915	a	a	DT
1916	1921	novel	novel	JJ
1922	1928	target	target	NN
1929	1931	of	of	IN
1932	1936	drug	drug	NN
1937	1948	development	development	NN
1949	1952	for	for	IN
1953	1962	treatment	treatment	NN
1963	1965	of	of	IN
1966	1978	inflammation	inflammation	NN
1978	1979	,	,	,
1980	1993	atherogenesis	atherogenesis	NN
1993	1994	,	,	,
1995	1998	and	and	CC
1999	2004	tumor	tumor	NN
2005	2015	metastasis	metastasis	NN
2015	2016	.	.	.